Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Z. PAN (Heidelberg, Germany), C. Eichstaedt (Heidelberg, Germany), N. Benjamin (Heidelberg, Germany), N. Blank (Heidelberg, Germany), H. Lorenz (Heidelberg, Germany), C. Fiehn (Baden-Baden, Germany), J. Song (Heidelberg, Germany), P. Xanthouli (Heidelberg, Germany), S. Harutyunova (Heidelberg, Germany), B. Egenlauf (Heidelberg, Germany), A. Marra (Naples, Italy), C. Fischer (Heidelberg, Germany), E. Grünig (Heidelberg, Germany). Early treatment of borderline pulmonary arterial hypertension associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group, proof-of-concept study. 272

Member's Comments

No comment yet.

Related content which might interest you: Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical Trials: "Aerosolized Lancovutide (Moli1901)" and "Oral Sildenafil" Year: 2009 Oral sildenafil treatment in children with pulmonary arterial hypertension (PAH): results of a double-blind, placebo-controlled, dose-ranging study Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 LATE-BREAKING ABSTRACT: COPD-associated severe pulmonary hypertension (COPDPH): results of a 16-weeks prospective multicenter, double-blind, placebo-controlled randomized clinical trial (RCT) [SPHERIC-1 (http://clinicaltrials.gov/ct2/show/NCT01441934)] investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2. Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol Source: ERJ Open Res, 5 (4) 00186-2019; 10.1183/23120541.00186-2019 Year: 2019 End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009 Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Source: Eur Respir J 2002; 20: 245 Year: 2002 Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial. Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020 Use of bosentan for the treatment of pulmonary arterial hypertension in Spain: a multicenter, retrospective, observational study Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Cicletanine in pulmonary arterial hypertension (PAH): Results from a phase 2 randomized placebo-controlled trial Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 PULSAR: A phase 2, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of sotatercept (ACE-011) when added to standard of care (SOC) for treatment of pulmonary arterial hypertension (PAH) Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Pulmonary vasodilator therapy in severe COPD: a double-blind, placebo-controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 525s Year: 2007 A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007 Imatinib in pulmonary arterial hypertension, a randomized, efficacy study (IMPRES) Source: Annual Congress 2011 - Treatments for pulmonary hypertension in human and experimental models Year: 2011 A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018 Year: 2019 A prospective randomised double-blind placebo controlled trial of venlafaxine in patients with stable chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 32s Year: 2006 Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 RCT Abstract - Using a smartphone application in COPD patients to increase physical activity following pulmonary rehabilitation. Results of the AMOPUR Study, a multicenter, randomized, controlled study Source: Virtual Congress 2021 – A multidisciplinary approach to the management of chronic respiratory diseases Year: 2021 Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Source: Eur Respir J 2013; 42: 1622-1632 Year: 2013